Assyro AI

Orange Book product · Brand (NDA)

MIUDELLA

COPPER

Brand (NDA)NDA 218201RX SEBELA WOMENS HLTH

At a glance

Feb 24, 2025

Approved

Brand (NDA)

Application

Not listed

TE code

14

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Feb 24, 2025

    1 yr 4 mo ago

  2. Today

  3. Exclusivity ends · NP

    New product exclusivity (3 years)

    Feb 24, 2028

    in 1 yr 9 mo

  4. Patent 10159596 expires

    Listed drug product patent expiration.

    Aug 14, 2032

    in 6 yr 3 mo

  5. Patent 10188546 expires

    Listed drug product patent expiration.

    Aug 14, 2032

    in 6 yr 3 mo

  6. Patent 11850181 expires

    Listed drug product patent expiration.

    Aug 14, 2032

    in 6 yr 3 mo

  7. Patent 9427351 expires

    Listed drug product patent expiration.

    Aug 14, 2032

    in 6 yr 3 mo

  8. Patent 9089418 expires

    Listed drug product patent expiration.

    Apr 09, 2033

    in 6 yr 11 mo

  9. Patent 12138199 expires

    Listed drug product patent expiration.

    Oct 18, 2033

    in 7 yr 5 mo

  10. Patent 10398588 expires

    Listed drug product patent expiration.

    Feb 24, 2034

    in 7 yr 10 mo

  11. Patent 9610191 expires

    Listed method-of-use patent (U-4155) expiration.

    Feb 24, 2034

    in 7 yr 10 mo

  12. Patent 10022264 expires

    Listed drug product patent expiration.

    Mar 22, 2034

    in 7 yr 10 mo

  13. Patent 9180040 expires

    Listed drug product patent expiration.

    Mar 22, 2034

    in 7 yr 10 mo

  14. Patent 9265652 expires

    Listed method-of-use patent (U-4155) expiration.

    Apr 28, 2034

    in 8 yr

  15. Patent 10166141 expires

    Listed drug product patent expiration.

    Jun 13, 2034

    in 8 yr 1 mo

  16. Patent 11207209 expires

    Listed drug product patent expiration.

    Aug 16, 2034

    in 8 yr 3 mo

  17. Patent 10918516 expires

    Listed drug product patent expiration.

    Jan 23, 2037

    in 10 yr 9 mo

Pharmaceutical detail

Active ingredient

COPPER

Strength

N/A

Dosage form

SYSTEM

Route

INTRAUTERINE

TE code

Not listed

Application

NDA 218201

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (1)

  • NPNew product exclusivity (3 years)

    Feb 24, 2028

    in 1 yr 9 mo

Listed patents (14)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10159596Aug 14, 2032in 6 yr 3 mo
Product
10188546Aug 14, 2032in 6 yr 3 mo
Product
11850181Aug 14, 2032in 6 yr 3 mo
Product
9427351Aug 14, 2032in 6 yr 3 mo
Product
9089418Apr 09, 2033in 6 yr 11 mo
Product
12138199Oct 18, 2033in 7 yr 5 mo
Product
10398588Feb 24, 2034in 7 yr 10 mo
ProductU-4155
9610191Feb 24, 2034in 7 yr 10 mo
U-4155
10022264Mar 22, 2034in 7 yr 10 mo
Product
9180040Mar 22, 2034in 7 yr 10 mo
Product
9265652Apr 28, 2034in 8 yr
U-4155
10166141Jun 13, 2034in 8 yr 1 mo
Product
11207209Aug 16, 2034in 8 yr 3 mo
Product
10918516Jan 23, 2037in 10 yr 9 mo
Product
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.